Notícias

Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.

J&J has more than 28 sources of blockbuster revenue.

Investors didn't seem to think so after the company published it.

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...

The healthcare company posted $25.31 billion in quarterly sales and raised its annual sales forecast to about $101.1 billion at the midpoint

Johnson & Johnson (NYSE:JNJ) reported stronger-than-expected second-quarter results and raised its full-year earnings outlook, although the healthcare company’s shares slipped around 1 percent in premarket trading on Wednesday. Earnings and revenue beat expectationsThe company posted adjusted earnings per share of 2.

Investing.com -- Johnson & Johnson (NYSE:JNJ) reported second-quarter results that exceeded Wall Street expectations, though shares are down around 1% premarket on Wednesday.

By Michael Erman July 15 (Reuters) - Johnson & Johnson beat Wall Street estimates for second-quarter sales and profit on Wednesday, as strong growth from immunology drug Tremfya and cancer blockbuster

Johnson & Johnson stock is Monday's IBD Stock Of The Day. The medical bellwether will report its June-quarter earnings next week.

Shares of Medtronic jumped 5% Wednesday after the medical-device maker reported better-than-expected quarterly results, helped by strong sales of devices used in heart procedures. The company also said it applied for U.

HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.